Scholarlink

Background <p>mRNA vaccines have garnered significant attention due to their rapid development and high efficacy, as demonstrated during the COVID-19 pandemic. Respiratory Syncytial Virus (RSV) remains a major cause&#xa0;of respiratory illness, particularly among infants and the elderly, with limited effective vaccine options.&#xa0;This study aimed to develop a lipid nanoparticle (LNP) formulation for an mRNA vaccine targeting the G glycoprotein of RSV.</p> Methods <p>The LNP formulation was optimized through comprehensive in vitro and in vivo screening. The optimized LNP was used to deliver mRNA encoding the conserved core fragment of RSV G glycoprotein. Immune responses and protective efficacy were evaluated through preclinical studies.</p> Results <p>The optimized LNP demonstrated superior mRNA expression and stability, inducing high levels of G&#xa0;glycoprotein-specific antibodies and robust T-cell responses. The mRNA/LNP vaccine conferred complete protection against RSV challenge without adverse effects.</p> Conclusions <p>The mRNA/LNP vaccine targeting the conserved region of the RSV G glycoprotein elicited strong immune responses and demonstrated a favorable safety profile, suggesting its potential as an effective&#xa0;preventive strategy against RSV infection. This study provides valuable insights into the design of LNP-based&#xa0;mRNA vaccines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of lipid nanoparticle formulation for intramuscular administration of mRNA vaccine against respiratory syncytial virus

  • 期刊论文

  • 发表日期：

    2025年1月22日

查看全文
  • Eunju Jang,
  • Yeji Lee,
  • Eunju Ko,
  • Michaela Jeong,
  • Jun Chang,
  • Hyukjin Lee

摘要

Background

mRNA vaccines have garnered significant attention due to their rapid development and high efficacy, as demonstrated during the COVID-19 pandemic. Respiratory Syncytial Virus (RSV) remains a major cause of respiratory illness, particularly among infants and the elderly, with limited effective vaccine options. This study aimed to develop a lipid nanoparticle (LNP) formulation for an mRNA vaccine targeting the G glycoprotein of RSV.

Methods

The LNP formulation was optimized through comprehensive in vitro and in vivo screening. The optimized LNP was used to deliver mRNA encoding the conserved core fragment of RSV G glycoprotein. Immune responses and protective efficacy were evaluated through preclinical studies.

Results

The optimized LNP demonstrated superior mRNA expression and stability, inducing high levels of G glycoprotein-specific antibodies and robust T-cell responses. The mRNA/LNP vaccine conferred complete protection against RSV challenge without adverse effects.

Conclusions

The mRNA/LNP vaccine targeting the conserved region of the RSV G glycoprotein elicited strong immune responses and demonstrated a favorable safety profile, suggesting its potential as an effective preventive strategy against RSV infection. This study provides valuable insights into the design of LNP-based mRNA vaccines.